Percutaneous Transluminal Angioplasty of Lower Limb Arteries Causes a Systemic Inflammatory Response

Annals of Vascular Surgery

Volumn 23, Issue 5, 2009, Pages 569-576

  Parmar, Jitesh H ^a   Aslam, Mo ^a   Standfield, Nigel J ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; FOLLOW UP; HUMAN; ISCHEMIA; LEG ANGIOGRAPHY; LEG ARTERY; MALE; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; REPERFUSION INJURY; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

AGED; ANGIOPLASTY, BALLOON; ARTERIAL OCCLUSIVE DISEASES; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FEMALE; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-10; INTERLEUKIN-6; INTERLEUKIN-8; ISCHEMIA; LOWER EXTREMITY; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECURRENCE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TIME FACTORS; TREATMENT FAILURE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 69849109241     PISSN: 08905096     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.avsg.2009.02.004     Document Type: Article

References (33)

1. Hughson W.G., Mann J.I., and Garrod A. Intermittent claudication: prevalence and risk factors. Br Med J 1 (1978) 1379-1381
2. Fowkes F.G., Housley E., Cawood E.H., Macintyre C.C., Ruckley C.V., and Prescott R.J. Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. Int J Epidemiol 20 (1991) 384-392
3. Hospital inpatient inquiry. Main tables (1986), Her Majesty's Stationary Office, London, UK. http://www.opsi.gov.uk Department of Health & Social Security. Avilable at http://www.opsi.gov.uk
4. Pentecost M.J., Criqui M.H., Dorros G., et al. Guidelines for peripheral percutaneous transluminal angioplasty of the abdominal aorta and lower extremity vessels. A statement for health professionals from a Special Writing Group of the Councils on Cardiovascular Radiology, Arteriosclerosis, Cardio-Thoracic and Vascular Surgery, Clinical Cardiology, and Epidemiology and Prevention, the American Heart Association. J Vasc Interv Radiol 14 (2003) S495-S515
5. Schillinger M., Exner M., Mlekusch W., et al. Fibrinogen predicts restenosis after endovascular treatment of the iliac arteries. Thromb Haemost 87 (2002) 959-965
6. Tschopl M., Tsakiris D.A., Marbet G.A., Labs K.H., and Jager K. Role of hemostatic risk factors for restenosis in peripheral arterial occlusive disease after transluminal angioplasty. Arterioscler Thromb Vasc Biol. 17 (1997) 3208-3214
7. Kovacevic T., Van Der Loo B., Amann-Vesti B.R., Rousson V., and Koppensteiner R. Plasma homocysteine and restenosis after femoropopliteal angioplasty. J Endovasc Ther 11 (2004) 302-309
8. Vardanian A.J., Busuttil R.W., and Kupiec-Weglinski J.W. Molecular mediators of liver ischemia and reperfusion injury: a brief review. Mol Med 14 (2008) 337-345
9. Wehrens X.H., Rouwet E.V., oude Egbrink M.G., Slaaf D.W., and Ramsay G. Effects of experimental lower-limb ischaemia-reperfusion injury on the mesenteric microcirculation. Br J Surg 89 (2002) 185-191
10. Grace P.A. Ischaemia Reperfusion Injury (1999), Blackwell Science, London
11. Hasenstab D., Lea H., Hart C.E., Lok S., and Clowes A.W. Tissue factor overexpression in rat arterial neointima models thrombosis and progression of advanced atherosclerosis. Circulation 101 (2000) 2651-2657
12. Patterson C., Stouffer G.A., Madamanchi N., and Runge M.S. New tricks for old dogs: nonthrombotic effects of thrombin in vessel wall biology. Circ Res. 88 (2001) 987-997
13. Davis C., Fischer J., Ley K., and Sarembock I.J. The role of inflammation in vascular injury and repair. J Thromb Haemost 1 (2003) 1699-1709
14. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 340 (1999) 115-126
15. Esmon C.T. Inflammation and thrombosis. J Thromb Haemost 1 (2003) 1343-1348
16. Ridker P.M., Cushman M., Stampfer M.J., Tracy R.P., and Hennekens C.H. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation 97 (1998) 425-428
17. Schillinger M., Exner M., Mlekusch W., et al. Vascular inflammation and percutaneous transluminal angioplasty of the femoropopliteal artery: association with restenosis. Radiology 225 (2002) 21-26
18. Rutherford R.B., Baker J.D., Ernst C., et al. Recommended standards for reports dealing with lower extremity ischemia: revised version. J Vasc Surg 26 (1997) 517-538
19. Libby P., and Simon D.I. Inflammation and thrombosis: the clot thickens. Circulation 103 (2001) 1718-1720
20. Kranzhofer R., Clinton S.K., Ishii K., Coughlin S.R., Fenton II J.W., and Libby P. Thrombin potently stimulates cytokine production in human vascular smooth muscle cells but not in mononuclear phagocytes. Circ Res. 79 (1996) 286-294
21. Fiorentino D.F., Bond M.W., and Mosmann T.R. Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med 170 (1989) 2081-2095
22. Bown M.J., Nicholson M.L., Bell P.R., and Sayers R.D. Cytokines and inflammatory pathways in the pathogenesis of multiple organ failure following abdominal aortic aneurysm repair. Eur J Vasc Endovasc Surg 22 (2001) 485-495
23. Norwood M.G., Bown M.J., Sutton A.J., Nicholson M.L., and Sayers R.D. Interleukin 6 production during abdominal aortic aneurysm repair arises from the gastrointestinal tract and not the legs. Br J Surg 91 (2004) 1153-1156
24. Kirk G., Hickman P., McLaren M., Stonebridge P.A., and Belch J.J. Interleukin-8 (IL-8) may contribute to the activation of neutrophils in patients with peripheral arterial occlusive disease (PAOD). Eur. J Vasc Endovasc Surg 18 (1999) 434-438
25. Lin E., Calvano S.E., and Lowry S.F. Inflammatory cytokines and cell response in surgery. Surgery 127 (2000) 117-126
26. Tracey K.J., Beutler B., Lowry S.F., et al. Shock and tissue injury induced by recombinant human cachectin. Science 234 (1986) 470-474
27. Bartholomew J.R., and Olin J.W. Pathophysiology of peripheral arterial disease and risk factors for its development. Cleve Clin J Med 73 Suppl. 4 (2006) S8-S14
28. Hobbs S.D., Marshall T., Fegan C., Adam D.J., and Bradbury A.W. The constitutive procoagulant and hypofibrinolytic state in patients with intermittent claudication due to infrainguinal disease significantly improves with percutaneous transluminal balloon angioplasty. J Vasc Surg 43 (2006) 40-46
29. Caixeta A.M., Brito Jr. F.S., Costa M.A., Serrano Jr. C.V., Petriz J.L., and Da Luz P.L. Enhanced inflammatory response to coronary stenting marks the development of clinically relevant restenosis. Catheter Cardiovasc Interv 69 (2007) 500-507
30. Monraats P.S., Kurreeman F.A., Pons D., et al. Interleukin 10: a new risk marker for the development of restenosis after percutaneous coronary intervention. Genes Immun 8 (2007) 44-50
31. Monraats P.S., Pires N.M., Schepers A., et al. Tumor necrosis factor-alpha plays an important role in restenosis development. FASEB J 19 (2005) 1998-2004
32. Brunetti N.D., Munno I., Pellegrino P.L., et al. Inflammatory cytokine imbalance after coronary angioplasty: links with coronary atherosclerosis. J Interv Cardiol 20 (2007) 248-257
33. Schillinger M., Haumer M., Schlerka G., et al. Restenosis after percutaneous transluminal angioplasty in the femoropopliteal segment: the role of inflammation. J Endovasc Ther 8 (2001) 477-483